In exam rooms across Cleveland, parents are suddenly staring down a new wave of kids' weight loss medicines as GLP-1 drugs move into pediatric care. Some treatments are now FDA-approved for teens, and clinical trials suggest younger children may also benefit, but the tradeoffs are real. Families and pediatricians say the decision often comes down to safety, insurance hurdles and long-term unknowns.
What's changed: approvals and trials
Semaglutide, sold as Wegovy for chronic weight management, is FDA-approved for patients 12 years and older, according to the FDA. A randomized trial published in the New England Journal of Medicine found that liraglutide produced greater BMI reductions than placebo in children aged 6 to under 12 when added to lifestyle support. Those findings have kicked off additional regulatory review and, in clinic, have widened the menu of options without fully answering who should be treated or when to start.
How the drugs are used and what to watch for
GLP-1 receptor agonists work by reducing appetite and slowing how quickly the stomach empties. Clinicians typically pair the medication with intensive dietary counseling, behavior support and physical activity, according to the American Academy of Pediatrics. In trials, families most often reported side effects such as decreased appetite and nausea, and some kids experienced vomiting or diarrhea. “We are watching these data constantly and very carefully,” pediatric specialist Scott Hadland told LocalMemphis. Because the drugs act on appetite and the brain, clinicians also screen for eating-disorder risk and keep a close eye on growth and development throughout treatment.
Coverage and costs vary for families
Insurance coverage is all over the map. Some state Medicaid programs and commercial plans cover GLP-1s for eligible adolescents, while others require prior authorization or restrict use to kids who meet specific clinical criteria, according to insurer policy documents such as those from Meridian/Centene. That patchwork can leave families staring at big out-of-pocket bills or waiting through long approval processes while providers document prior treatments and related health problems. Local health advocates warn that these access gaps risk deepening inequities in obesity care unless coverage is broadened and tied to comprehensive pediatric services, not just a prescription.
Questions parents should ask their pediatrician
Pediatricians say the choice to start a GLP-1 should be individualized, not automatic. That usually means a full workup for related conditions such as high blood pressure, diabetes risk and fatty liver disease, along with routine mental health screening, per the American Academy of Pediatrics. Parents are encouraged to ask about expected benefits and timelines, the most likely side effects, how their child's growth will be tracked, what the exit plan looks like for eventually stopping the medication and whether nutritional and behavioral supports are baked into follow-up care.
What we still don’t know
Long-term safety and how durable the weight loss will be in children are still big question marks. Data are being collected from ongoing trials and extension studies, so clinicians currently lean toward cautious, closely monitored use rather than a wide-open rollout, according to trial publications in the New England Journal of Medicine. For Cleveland families weighing their options, experts say the most important step is a careful, unhurried conversation with a pediatrician or pediatric endocrinologist about risks, potential benefits and how medicine can fit into a broader plan built on proven lifestyle supports.
